See more : Zilltek Technology Corp. (6679.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Stealth BioTherapeutics Corp (MITO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Stealth BioTherapeutics Corp, a leading company in the Biotechnology industry within the Healthcare sector.
- Kuros Biosciences AG (CSBTF) Income Statement Analysis – Financial Results
- Bilibili Inc. (9626.HK) Income Statement Analysis – Financial Results
- Monotype India Limited (MONOT.BO) Income Statement Analysis – Financial Results
- ArcelorMittal South Africa Ltd (ARCXF) Income Statement Analysis – Financial Results
- Green EnviroTech Holdings Corp. (GETH) Income Statement Analysis – Financial Results
Stealth BioTherapeutics Corp (MITO)
About Stealth BioTherapeutics Corp
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 21.09M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 21.09M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.56M | 29.31M | 44.60M | 53.06M | 63.22M | 48.45M |
| General & Administrative | 19.75M | 19.37M | 22.32M | 22.22M | 16.50M | 13.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.75M | 19.37M | 22.32M | 22.22M | 16.50M | 13.40M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 46.30M | 48.67M | 66.92M | 75.28M | 79.72M | 61.85M |
| Cost & Expenses | 46.30M | 48.67M | 66.92M | 75.28M | 79.72M | 61.85M |
| Interest Income | 3.00K | 139.00K | 988.00K | 195.09K | 56.84K | 799.02K |
| Interest Expense | 1.24M | 1.81M | 6.67M | 21.36M | 3.28M | 0.00 |
| Depreciation & Amortization | 77.00K | 232.00K | 284.00K | 309.04K | 346.87K | 312.54K |
| EBITDA | -51.21M | -55.42M | -64.78M | -75.05M | -79.28M | -60.74M |
| EBITDA Ratio | 0.00% | 0.00% | -307.19% | 0.00% | 0.00% | 0.00% |
| Operating Income | -51.29M | -48.67M | -45.83M | -75.28M | -79.72M | -61.85M |
| Operating Income Ratio | 0.00% | 0.00% | -217.35% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.22M | -8.79M | -25.90M | -21.43M | -3.19M | 799.02K |
| Income Before Tax | -52.53M | -57.46M | -71.73M | -96.71M | -82.91M | -61.05M |
| Income Before Tax Ratio | 0.00% | 0.00% | -340.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.24M | -6.98M | -19.23M | -76.21K | 92.30K | 799.02K |
| Net Income | -53.77M | -57.46M | -71.73M | -96.71M | -82.91M | -61.05M |
| Net Income Ratio | 0.00% | 0.00% | -340.15% | 0.00% | 0.00% | 0.00% |
| EPS | -1.16 | -1.24 | -2.29 | -2.93 | -5.22 | -2.99 |
| EPS Diluted | -1.16 | -1.24 | -2.29 | -2.93 | -5.22 | -2.99 |
| Weighted Avg Shares Out | 46.35M | 46.35M | 31.31M | 33.02M | 15.88M | 20.38M |
| Weighted Avg Shares Out (Dil) | 46.35M | 46.35M | 31.31M | 33.02M | 15.88M | 20.38M |
Stealth BioTherapeutics Showcases Data for Elamipretide in Dry Age-Related Macular Degeneration at the 2021 ARVO Annual Meeting
Stealth BioTherapeutics Announces Poster Presentation at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting
Stealth BioTherapeutics CEO to Give Keynote Presentation at Mitochondria-Targeted Drug Development Summit
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q4 2020 Results - Earnings Call Transcript
Stealth BioTherapeutics Reports Fiscal Year 2020 Financial Results And Recent Business Highlights
Stealth BioTherapeutics to Report Full Year 2020 Financial Results on Tuesday, April 6, 2021
Stealth BioTherapeutics Granted Pre-NDA Meeting For Elamipretide As A Treatment For Cardiomyopathy In Barth Syndrome
Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases
Stealth BioTherapeutics (MITO) CEO Reenie McCarthy on Q3 2020 Results - Earnings Call Transcript
Stealth BioTherapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights
Source: https://incomestatements.info
Category: Stock Reports